about
Polo kinase Cdc5 associates with centromeres to facilitate the removal of centromeric cohesin during mitosisA mechanism for the elimination of the female gamete centrosome in Drosophila melanogasterStructure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoniIdentification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assayCurrent progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents.Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.Interactions of Prototype Foamy Virus Capsids with Host Cell Polo-Like Kinases Are Important for Efficient Viral DNA Integration.Cdk1 plays matchmaker for the Polo-like kinase and its activator SPAT-1/Bora.Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domainRecent Advances and New Strategies in Targeting Plk1 for Anticancer TherapyHow to make a static cytokinetic furrow out of traveling excitable waves.Phosphorylation of LSD1 by PLK1 promotes its chromatin release during mitosis.Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.The Bub1-Plk1 kinase complex promotes spindle checkpoint signalling through Cdc20 phosphorylation.Phosphatase-Stable Phosphoamino Acid Mimetics That Enhance Binding Affinities with the Polo-Box Domain of Polo-like Kinase 1.Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy.Prophase I: Preparing Chromosomes for Segregation in the Developing Oocyte.Playing polo during mitosis: PLK1 takes the lead.Reduced kinase activity of polo kinase Cdc5 affects chromosome stability and DNA damage response in S. cerevisiae.Polo-like-kinase 1 is a proviral host-factor for hepatitis B virus replication.In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases.Silencing of karyopherin α2 inhibits cell growth and survival in human hepatocellular carcinomaKinases Involved in Both Autophagy and Mitosis.Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancerApplication of oxime-diversification to optimize ligand interactions within a cryptic pocket of the polo-like kinase 1 polo-box domain.Regulation of the polo kinase during cytokinesis.Mitotic entry: The interplay between Cdk1, Plk1 and Bora.The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation.Coupling of Polo kinase activation to nuclear localization by a bifunctional NLS is required during mitotic entry.SUMOylation regulates the localization and activity of Polo-like kinase 1 during cell cycle in the silkworm, Bombyx mori.Identification of volasertib-resistant mechanism and evaluation of combination effects with volasertib and other agents on acute myeloid leukemia.Expression Profiling of Differentiating Emerin-Null Myogenic Progenitor Identifies Molecular Pathways Implicated in Their Impaired Differentiation.Polo-like kinase 1 inhibition results in misaligned chromosomes and aberrant spindles in porcine oocytes during the first meiotic division.Polo-like kinase 1 (PLK1)-dependent phosphorylation of methylenetetrahydrofolate reductase (MTHFR) regulates replication via histone methylation.TRAP1 controls cell cycle G2-M transition through the regulation of CDK1 and MAD2 expression/ubiquitination.Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators.Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines.Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia.
P2860
Q27937317-B0E5FB86-D1FF-42C6-AD4E-A7BD2C3FBDB8Q28275930-45A1B22E-2B46-4120-AC3C-DD46DA714AAEQ28552326-5904C624-60B3-48FA-8C6B-088E73A59EBAQ28820936-1142B556-C786-42D6-B58A-F008D91BFCECQ33873351-B95C9411-6605-4197-8BB5-D285A127A74AQ35867866-915D2C44-C464-45FD-B08E-7E5E5F6B4622Q36118484-B1D685A8-D54B-48EF-8940-F385F97A0E30Q36188452-790E2ABC-FA59-44A0-B6B0-61B257311BBEQ36207913-F7AD28D3-96C3-421B-A949-E1A2F6B735F9Q36386336-F940BAA6-CB75-423A-B39E-D97FBA92D7A0Q36997874-1C2C48E6-E880-4F0D-B3D0-DEC3DF726C32Q37719701-6B3F392E-5731-41E4-A5D2-EF9709A65C00Q38310745-05060176-5915-4BFC-A66C-7ADDE99406A9Q38707137-F823B96F-9B68-49FB-AB88-23BCE2674E06Q38780845-A5CA76BE-D555-416B-979E-B60B8BDF6EFCQ38824242-3191266F-DC0C-4B2D-A364-253B91FE3E36Q39012724-EF65BF13-EDA6-413D-A0D8-3DCBE303FCEEQ39155608-F04A57EE-3395-4072-9030-E0AFD262FDDFQ39258525-09C7C1F2-44BE-4F7A-88A7-85547A0189D2Q39450140-E0875F13-B179-45E1-8F39-CC9E376E13CBQ40226856-E1CFF6C1-EBEC-4990-980D-5CB101CB8620Q40997106-E263B84B-F584-4547-A2FB-B1A907094CCAQ41055921-379064FE-29A7-4035-BFD1-9373CDE864F0Q41661088-EE64C1C1-9D92-4582-9911-2A6E7A57C8F4Q42274998-AD254190-2E25-48D3-B10A-C7CE781EF7B0Q42383972-6DB91236-ECFB-4404-95C1-7BE0F1D28486Q43195535-4DEDF133-476E-4E15-9C04-F135648CB0D5Q44993538-9E340AE2-6209-4EA2-AB03-99FE7B80E5A8Q47143539-A7D60B35-5CF6-4588-AFD7-29AEFB0604C4Q47143828-F0D40640-AE54-4ACE-8E13-97ECDE98E464Q47147377-BCBB7147-C1C1-4462-9F54-C3D71AFF629AQ47151856-12EBD7D5-1BE1-491B-BF06-14CE3DB24127Q47170895-FCF501AA-4BBD-4BEF-A2AC-B25C16CA52B0Q47397392-F78DEF1F-39BB-421C-BDAC-C64215EF44EFQ47935910-A234A88F-03BA-4919-86A7-7765FB430361Q48175424-84708128-FC26-48BE-8472-A64ECA1F99F3Q50994164-2806BD6A-8E04-45D9-A322-DA9204488ED5Q51101229-426C69C7-5B11-4021-ABD0-52E10BA7D06FQ51763031-44EB9E55-7772-49A1-B876-5A9D0BD6791FQ52668213-DE30E8CF-500D-4489-92B0-E8DCB65CD1FD
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Understanding the Polo Kinase machine.
@en
type
label
Understanding the Polo Kinase machine.
@en
prefLabel
Understanding the Polo Kinase machine.
@en
P2093
P2860
P356
P1433
P1476
Understanding the Polo Kinase machine.
@en
P2093
D Kachaner
V Archambault
P2860
P2888
P304
P356
10.1038/ONC.2014.451
P407
P577
2015-01-26T00:00:00Z
P6179
1016481127